Craft
  • Home
  •  / Guardant Health
Guardant Health

Guardant Health

Tests to Clinical Customers Sold

87.6 K

FY, 2021

Revenue

$373.7 M

FY, 2021

Market Capitalization

$5.7 B

2022-09-20

Guardant Health Summary

Company summary

Overview
Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Its digital sequencing technology provides a picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment.
Type
Public
Founded
2012
HQ
Redwood City, CA, US | view all locations
Website
https://guardanthealth.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Helmy Eltoukhy

    Helmy Eltoukhy, Chairman and Co-Chief Executive Officer

  • Ian Clark, Lead Independent Director

    • AmirAli Talasaz

      AmirAli Talasaz, Co-Chief Executive Officer

    • Michael Wiley

      Michael Wiley, Head of Corporate Affairs

      Operating MetricsView all

      Facilities Leased, sq. ft.

      163K

      FY, 2021

      Tests to Clinical Customers Sold

      87.6K
      38.5%

      FY, 2021

      Tests to Biopharmaceutical Customers Sold

      18.6K
      16.4%

      FY, 2021

      LocationsView all

      1 location detected

      • Redwood City, CA HQ

        United States

        505 Penobscot Dr

      Guardant Health Financials

      Summary financials

      Revenue (Q2, 2022)
      $109.1M
      Gross profit (Q2, 2022)
      $72.4M
      Net income (Q2, 2022)
      ($229.4M)
      Cash (Q2, 2022)
      $215.2M
      EBIT (Q2, 2022)
      ($130.3M)
      Enterprise value
      $6.8B

      Footer menu